Antiretroviral Combinations clinical trials

Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1

This study is looking at a new once-weekly tablet called islatravir/lenacapavir (ISL/LEN) for people living with HIV-1. It compares switching to this new tablet with continuing their current daily HIV treatment to see if it's safe and works well.